
2024.6-至今 ??中國科學院生物與化學交叉研究中心,研究員、課題組長
2020.1-2024.5 ?美國密歇根大學醫(yī)學院,博士后
2019.7-2020.1 ?中國科學院上海有機化學研究所,助理研究員
2016.9-2019.6 ?中國科學院上海有機化學研究所,有機化學博士
2013.9-2016.6 ?南昌大學/中國科學院上海藥物研究所,藥物化學碩士
2012.7-2013.8 ?中國科學院上海藥物研究所,本科畢業(yè)設(shè)計
2009.9-2013.7 ?南昌大學,藥學本科
1. 靶向蛋白降解的抗神經(jīng)退行性疾病的藥物發(fā)現(xiàn)和成藥性優(yōu)化
2. 基于分子膠技術(shù)的藥物開發(fā)及其作用機制研究
3. 針對潛在新靶標的小分子調(diào)節(jié)劑的開發(fā)和化學生物學研究
2019年:中國科學院優(yōu)秀畢業(yè)生
2019年:北京市優(yōu)秀畢業(yè)生
1.?Zhixiang Chen, Yongwen Jiang, Li Zhang, Yinlong Guo, Dawei Ma. Oxalic diamides and tert-butoxides: Two types of ligands enabling practical access to alkyl aryl ethers via Cu-catalyzed coupling reaction. Journal of the American Chemical Society,?2019, 141, 3541. (ESI高被引論文)
2.?Zhixiang Chen,#?Mi Wang,#?Dimin Wu,#?Longchuan Bai, Tianfeng Xu, Hoda Metwally, Yu Wang, Donna McEachern, Lijie Zhao, Ruiting Li, John Takyi-Williams, Meilin Wang, Lu Wang, Qiuxia Li, Bo Wen, Duxin Sun, Shaomeng Wang. Discovery of CBPD-268 as an exceptionally potent and orally efficacious CBP/p300 PROTAC degrader capable of achieving tumor regression. Journal of Medicinal Chemistry,?2024, 67, 5275. (被評為“Featured Article”)
3.?Zhixiang Chen,#?Mi Wang,# Dimin Wu, Lijie Zhao, Hoda Metwally, Wei Jiang, Yu Wang, Longchuan Bai, Donna McEachern, Jie Luo, Meilin Wang, Qiuxia Li, Aleksas Matvekas, Bo Wen, Duxin Sun, Arul M Chinnaiyan, Shaomeng Wang. Discovery of CBPD-409 as a highly potent, selective, and orally efficacious CBP/p300 PROTAC degrader for the treatment of advanced prostate cancer.?Journal of Medicinal Chemistry,?2024, 67, 5351.
4.?Zhixiang Chen,#?Biao Hu,# Rohan Kalyan Rej,#?Dimin Wu,#?Ranjan Kumar Acharyya,#?Mingliang Wang,#?Tianfeng Xu,# Jianfeng Lu, Hoda Metwally, Yu Wang, Donna McEachern, Longchuan Bai, Christina L Gersch, Meilin Wang, Wenjing Zhang, Qiuxia Li, Bo Wen, Duxin Sun, James M Rae, Shaomeng Wang. Discovery of ERD-3111 as a potent and orally Efficacious estrogen receptor PROTAC degrader with strong antitumor activity. Journal of Medicinal Chemistry,?2023,?66, 12559.
5.?Jie Luo,#?Zhixiang Chen,#?Yuanyuan Qiao,# Jean Ching-Yi Tien, Eleanor Young, Rahul Mannan, Somnath Mahapatra, Tongchen He, Sanjana Eyunni, Yuping Zhang, Yang Zheng, Fengyun Su, Xuhong Cao, Rui Wang, Yunhui Cheng, Rithvik Seri, James George, Miriam Shahine, Stephanie J. Miner, Ulka Vaishampayan, Mi Wang, Shaomeng Wang,?Abhijit Parolia,?Arul M. Chinnaiyan. p300/CBP degradation is required to disable the active AR enhanceosome in prostate cancer. (bioRxiv, doi: https://doi.org/10.1101/2024.03.29.587346; Nature Genetics,?under review)
6.?Zhixiang Chen,#?Harshil Dhruv,#?Xuqing Zhang,#?Longchuan Bai,#?Rohan Kalyan Rej,#?Donna McEachern, Paul Kirchhoff, Rakesh Nagilla, Larry J. Jolivette, Cory T. Rice, Peter Orth, Corey O. Strickland, E. Scott Priestley, Helai P. Mohammad, Meilin Wang, Wenjing Zhang, Alejandra Duran, Bo Wen, Duxin Sun, Zhihua Sui, Shaomeng Wang. PVTX-405: a Potent, Highly Selective, and Orally Efficacious Molecular Glue Degrader of IKZF2 for the Treatment of Human Cancers. (Nature Communications, under review)
7.?Zhixiang Chen?and Dawei Ma. Cu/N,N’-dibenzyloxalamide catalyzed N-arylation of heteroanilines. Organic Letters, 2019, 21, 6874.
8.?Rohan Kalyan Rej,#?Biao Hu,#?Zhixiang Chen,#?Ranjan Kumar Acharyya,#?Dimin Wu,#?Hoda Metwally, Yu Wang, Wei Jiang, Longchuan Bai, Lorraine-Gersch Clark, Guozhang Xu, Weihong Zhang, Winston Wu, Scott Priestley, Zhihua Sui, Meilin Wang, Bo Wen, Duxin Sun, James M. Rae, Shaomeng Wang. Discovery of ERD-12310A as a Highly Potent and Orally Efficacious PROTAC Degrader of Estrogen Receptor α (ERα) for the Treatment of ER+ Human Breast Cancer. Journal of Medicinal Chemistry,?2024, https://doi.org/10.1021/acs.jmedchem.4c01401.
9.?Ranjan Kumar Acharyya,#?Rohan Kalyan Rej,#?Biao Hu,#?Zhixiang Chen,#?Dimin Wu,# Jianfeng Lu, Hoda Metwally, Donna McEachern, Yu Wang, Wei Jiang, Longchuan Bai, Jelena Tosovic, Lorraine-Gersch Clark, Guozhang Xu, Weihong Zhang, WenXue Wu, E. Scott Priestley, Zhihua Sui, Farzad Sarkari, Bo Wen, Duxin Sun, James M. Rae, Shaomeng Wang. Discovery of ERD-1233 as a Potent and Orally Efficacious Estrogen Receptor PROTAC Degrader for the Treatment of ER+ Human Breast Cancer. Journal of Medicinal Chemistry,?2024, 67, 19010.
10.?Zhixiang Chen,?Mengmeng Ning, Qingan Zou, Hua Cao, Yangliang Ye, Ying Leng, Jianhua Shen. Discovery and structure–activity relationship study of 4-phenoxythiazol-5-carboxamides as highly potent TGR5 agonists. Chemical and Pharmaceutical Bulletin, 2016,?64, 326.
11.?Hua Cao, Zhi-Xiang Chen, Kai Wang, Meng-Meng Ning, Qing-An Zou, Ying Feng, Yang-Liang Ye, Ying Leng, Jian-Hua Shen. Intestinally-targeted TGR5 agonists equipped with quaternary ammonium have an improved hypoglycemic e?ect and reduced gallbladder filling e?ect. Scientific Reports, 2016, 6, 28676.

